Patients with hormone-positive breast cancer are usually treated with hormone therapies such as tamoxifen or aromatase inhibitors. However, many of these patient's breast camcer become resistant to these drugs or develop resistance during treatment, allowing their breast cancer to return.

The Endocrinology team aims to understand how and why some patients’ cancers are resistant and others aren't.

Patients with triple negative breast cancer have limited treatment options because their breast tumours lack the receptors which targeted therapies like tamoxifen and Herceptin act against.